The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Saad, Farid ^a,b   Gooren, Louis J ^c  

^a BAYER PHARMA AG   (Germany)

^b GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960848642     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/471584     Document Type: Article

References (126)

1. Ogden C. L., Carroll M. D., Curtin L. R., McDowell M. A., Tabak C. J., Flegal K. M., Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 295 13 1549 1555 2-s2.0-33645523067 10.1001/jama.295.13. 1549
2. Janssen I., Mark A. E., Elevated body mass index and mortality risk in the elderly. Obesity Reviews 2007 8 1 41 59 2-s2.0-33845644669 10.1111/j.1467-789X.2006.00248.x (Pubitemid 44952834)
3. Blouin K., Boivin A., Tchernof A., Androgens and body fat distribution. Journal of Steroid Biochemistry and Molecular Biology 2008 108 3-5 272 280 2-s2.0-38749133682 10.1016/j.jsbmb.2007.09.001 (Pubitemid 351179628)
4. Wells J. C. K., Sexual dimorphism of body composition. Best Practice and Research 2007 21 3 415 430 2-s2.0-34548588284 10.1016/j.beem.2007.04.007 (Pubitemid 47387103)
5. Loomba-Albrecht L. A., Styne D. M., Effect of puberty on body composition. Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 1 10 15 2-s2.0-58849119597 10.1097/MED.0b013e328320d54c
6. Taylor R. W., rachael.taylor@otago.ac.nz Grant A. M., Williams S. M., Goulding A., Sex differences in regional body fat distribution from pre-to postpuberty. Obesity 2010 18 7 1410 1416 2-s2.0-61349179515 10.1038/oby.2009.399
7. Roemmich J. N., Clark P. A., Mai V., Berr S. S., Weltman A., Veldhuis J. D., Rogol A. D., Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. Journal of Clinical Endocrinology and Metabolism 1998 83 5 1440 1447 2-s2.0-0031796413 10.1210/jc.83.5.1440 (Pubitemid 28501000)
8. O'Connell J., Lynch L., Cawood J., The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010 5 4 e9997 10.1371/journal.pone.0009997
9. Björntorp P., Adipose tissue distribution and function. International Journal of Obesity 1991 15 supplement 2 67 81 2-s2.0-0026218543
10. Mayes J. S., Watson G. H., Direct effects of sex steroid hormones on adipose tissues and obesity. Obesity Reviews 2004 5 4 197 216 2-s2.0-7044250697 10.1111/j.1467-789X.2004.00152.x (Pubitemid 39423001)
11. Jensen M. D., Role of body fat distribution and the metabolic complications of obesity. Journal of Clinical Endocrinology and Metabolism 2008 93 11, supplement 1 S57 S63 2-s2.0-55849106577 10.1210/jc.2008-1585
12. Katznelson L., Rosenthal D. I., Rosol M. S., Anderson E. J., Hayden D. L., Schoenfeld D. A., Klibanski A., Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR 1998 170 2 423 427 2-s2.0-0031882392 (Pubitemid 28083851)
13. Katznelson L., Finkelstein J. S., Schoenfeld D. A., Rosenthal D. I., Anderson E. J., Klibanski A., Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. Journal of Clinical Endocrinology and Metabolism 1996 81 12 4358 4365 2-s2.0-0029838823 10.1210/jc.81.12.4358 (Pubitemid 26412044)
14. Smith M. R., Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004 63 4 742 745 2-s2.0-1842739187 10.1016/j.urology.2003.10.063 (Pubitemid 38479421)
15. Smith M. R., Lee H., Nathan D. M., Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 4 1305 1308 2-s2.0-33646029746 10.1210/jc.2005-2507
16. Basaria S., Muller D. C., Carducci M. A., Egan J., Dobs A. S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 106 3 581 588 2-s2.0-31544440178 10.1002/cncr.21642 (Pubitemid 43157621)
17. Derweesh I. H., DiBlasio C. J., Kincade M. C., Malcolm J. B., Lamar K. D., Patterson A. L., Kitabchi A. E., Wake R. W., Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International 2007 100 5 1060 1065 2-s2.0-35148842094 10.1111/j.1464-410X.2007.07184.x (Pubitemid 47537673)
18. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T.-P., Valkonen V.-P., Salonen R., Salonen J. T., Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004 27 5 1036 1041 2-s2.0-2342644814 10.2337/diacare.27.5.1036 (Pubitemid 38579762)
19. Kupelian V., Page S. T., Araujo A. B., Travison T. G., Bremner W. J., McKinlay J. B., Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. Journal of Clinical Endocrinology and Metabolism 2006 91 3 843 850 2-s2.0-33644828241 10.1210/jc.2005-1326 (Pubitemid 43357748)
20. Rosmond R., Wallerius S., Wanger P., Martin L., Holm G., Björntorp P., A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. Journal of Internal Medicine 2003 254 4 386 390 2-s2.0-0141862280 10.1046/j.1365-2796.2003.01205.x (Pubitemid 37211262)
21. Zmuda J. M., Cauley J. A., Kriska A., Glynn N. W., Gutai J. P., Kuller L. H., Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: a 13-year follow-up of former multiple risk factor intervention trial participants. American Journal of Epidemiology 1997 146 8 609 617 2-s2.0-0030693103 (Pubitemid 27454548)
22. Basaria S., Muller D. C., Carducci M. A., Egan J., Dobs A. S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 106 3 581 588 2-s2.0-31544440178 10.1002/cncr.21642 (Pubitemid 43157621)
23. Kannel W. B., Cupples L. A., Ramaswami R., Stokes J. III, Kreger B. E., Higgins M., Regional obesity and risk of cardiovascular disease; the Framingham Study. Journal of Clinical Epidemiology 1991 44 2 183 190 2-s2.0-0026092647 10.1016/0895-4356(91)90265-B
24. Björntorp P., Rosmond R., The metabolic syndrome-a neuroendocrine disorder? British Journal of Nutrition 2000 83 supplement 1 S49 S57 2-s2.0-0039634211 (Pubitemid 30319082)
25. Gans R. O. B., The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Medical Clinics of North America 2006 90 4 573 591 2-s2.0-33745839666 10.1016/j.mcna.2006.05.002 (Pubitemid 44037030)
26. Grundy S. M., Brewer H. B. Jr., Cleeman J. I., Smith S. C. Jr., Lenfant C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 2 e13 e18 2-s2.0-1842842014
27. Carr M. C., Brunzell J. D., Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. Journal of Clinical Endocrinology and Metabolism 2004 89 6 2601 2607 2-s2.0-2942683422 10.1210/jc.2004-0432 (Pubitemid 38766338)
28. Simmons R. K., Alberti K. G., Gale E. A, The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2009 53 4 600 605
29. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285 19 2486 2497 2-s2.0-0035897696 (Pubitemid 32433843)
30. Lakka H.-M., Laaksonen D. E., Lakka T. A., Niskanen L. K., Kumpusalo E., Tuomilehto J., Salonen J. T., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 288 21 2709 2716 2-s2.0-0037021505 10.1001/jama.288.21.2709 (Pubitemid 35403784)
31. Ford E. S., Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S. Diabetes Care 2005 28 11 2745 2749 2-s2.0-30544433479 10.2337/diacare.28.11.2745 (Pubitemid 43951170)
32. Alberti K. G. M. M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J.-C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009 120 16 1640 1645 2-s2.0-70350245011 10.1161/CIRCULATIONAHA.109.192644
33. Rodriguez A., Muller D. C., Metter E. J., Maggio M., Harman S. M., Blackman M. R., Andres R., Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. Journal of Clinical Endocrinology and Metabolism 2007 92 9 3568 3572 2-s2.0-34548759829 10.1210/jc.2006-2764 (Pubitemid 47435336)
34. Mohr B. A., Bhasin S., Link C. L., O'Donnell A. B., McKinlay J. B., The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts male aging study. European Journal of Endocrinology 2006 155 3 443 452 2-s2.0-33749065762 10.1530/eje.1.02241 (Pubitemid 44463951)
35. Kaplan S. A., kaplans@med.cornell.edu Meehan A. G., Shah A., The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the Implications for the relatively high incidence of erectile dysfunction observed in these men? The Journal of Urology 2006 176 4 1524 1528 2-s2.0-3142546340 10.1016/j.juro.2006.06.003 (Pubitemid 44307192)
36. Allan C. A., Strauss B. J., Burger H. G., Forbes E. A., McLachlan R. I., The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Medical Journal of Australia 2006 185 8 424 427 2-s2.0-33750177610 (Pubitemid 44596782)
37. Kalyani R. R., Dobs A. S., Androgen deficiency, diabetes, and the metabolic syndrome in men. Current Opinion in Endocrinology, Diabetes and Obesity 2007 14 3 226 234 2-s2.0-34247605052 10.1097/MED.0b013e32814db856 (Pubitemid 46684478)
38. Allan C. A., Strauss B. J. G., McLachlan R. I., Body composition, metabolic syndrome and testosterone in ageing men. International Journal of Impotence Research 2007 19 5 448 457 2-s2.0-34548458613 10.1038/sj.ijir.3901552 (Pubitemid 47367519)
39. Saad F., The role of testosterone in type 2 diabetes and metabolic syndrome in men. Arq Bras Endocrinol Metabol 2009 53 8 901 907
40. Svartberg J., Von Mühlen D., Sundsfjord J., Jorde R., Waist circumference and testosterone levels in community dwelling men. European Journal of Epidemiology 2004 19 7 657 663 2-s2.0-16544393474 10.1023/B:EJEP.0000036809.30558.8f (Pubitemid 41175133)
41. Kupelian V., Hayes F. J., Link C. L., Rosen R., McKinlay J. B., Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. Journal of Clinical Endocrinology and Metabolism 2008 93 9 3403 3410 2-s2.0-51649115358 10.1210/jc.2008-0054
42. Saad F., Gooren L., The role of testosterone in the metabolic syndrome: a review. Journal of Steroid Biochemistry and Molecular Biology 2009 114 1-2 40 43 2-s2.0-62949243871 10.1016/j.jsbmb.2008.12.022
43. Stanworth R. D., Jones T. H., Testosterone in obesity, metabolic syndrome and type 2 diabetes. Frontiers of Hormone Research 2009 37 74 90 2-s2.0-59849096860 10.1159/000176046
44. Stanworth R. D., Kapoor D., Channer K. S., Jones T. H., Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009 32 4 541 546 2-s2.0-65349083700 10.2337/dc08-1183
45. Stamler J., Stamler R., Riedlinger W. F., Algera G., Roberts R. H., Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. JAMA 1976 235 21 2299 2306 2-s2.0-0017314648 10.1001/jama.235.21.2299
46. Ding E. L., Song Y., Malik V. S., Liu S., Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006 295 11 1288 1299 2-s2.0-33644981693 10.1001/jama.295.11.1288
47. Traish A. M., Saad F., Guay A., The dark side of testosterone deficiency: II. type 2 diabetes and insulin resistance. Journal of Andrology 2009 30 1 23 32 2-s2.0-58149310816 10.2164/jandrol.108.005751
48. Yeap B. B., Hyde Z., Almeida O. P., Norman P. E., Chubb S. A. P., Jamrozik K., Flicker L., Hankey G. J., Lower testosterone levels predict incident stroke and transient ischemic attack in older men. Journal of Clinical Endocrinology and Metabolism 2009 94 7 2353 2359 2-s2.0-67650233470 10.1210/jc.2008-2416
49. Stellato R. K., Feldman H. A., Hamdy O., Horton E. S., Mckinlay J. B., Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000 23 4 490 494 2-s2.0-0034106347 (Pubitemid 30185792)
50. Haffner S. M., Shaten J., Stern M. P., Smith G. D., Kuller L., Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. American Journal of Epidemiology 1996 143 9 889 897 2-s2.0-0027503231 (Pubitemid 26131096)
51. Oh J.-Y., Barrett-Connor E., Wedick N. M., Wingard D. L., Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 2002 25 1 55 60 2-s2.0-0036357643 10.2337/diacare.25.1.55 (Pubitemid 41070783)
52. Haring R., Völzke H., Felix S. B., Schipf S., Dörr M., Rosskopf D., Nauck M., Schöfl C., Wallaschofski H., Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009 58 9 2027 2031 2-s2.0-70349105993 10.2337/db09-0031
53. Selvin E., Feinleib M., Zhang L., Rohrmann S., Rifai N., Nelson W. G., Dobs A., Basaria S., Golden S. H., Platz E. A., Androgens and diabetes in men: results from the third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007 30 2 234 238 2-s2.0-33846691958 10.2337/dc06-1579 (Pubitemid 46198324)
54. Yeap B. B., Chubb S. A. P., Hyde Z., Jamrozik K., Hankey G. J., Flicker L., Norman P. E., Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the health in men study. European Journal of Endocrinology 2009 161 4 591 598 2-s2.0-70349758939 10.1530/EJE-09-0348
55. Traish A. M., Saad F., Feeley R. J., Guay A., The dark side of testosterone deficiency: III. Cardiovascular disease. Journal of Andrology 2009 30 5 477 494 2-s2.0-68149138117 10.2164/jandrol.108.007245
56. Chandel A., Dhindsa S., Topiwala S., Chaudhuri A., Dandona P., Testosterone concentration in young patients with diabetes. Diabetes Care 2008 31 10 2013 2017 2-s2.0-56149107529 10.2337/dc08-0851
57. Stanworth R. D., Kapoor D., Channer K. S., Jones T. H., Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology 2008 159 6 739 746 2-s2.0-58149343861 10.1530/EJE-08-0266
58. Kaufman J. M., Vermeulen A., The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Reviews 2005 26 6 833 876 2-s2.0-26444515048 10.1210/er.2004-0013 (Pubitemid 41428540)
59. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. The Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
60. Lima N., Cavaliere H., Knobel M., Halpern A., Medeiros-Neto G., Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. International Journal of Obesity 2000 24 11 1433 1437 2-s2.0-0033304558
61. Pitteloud N., Hardin M., Dwyer A. A., Valassi E., Yialamas M., Elahi D., Hayes F. J., Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. Journal of Clinical Endocrinology and Metabolism 2005 90 5 2636 2641 2-s2.0-18844362098 10.1210/jc.2004-2190 (Pubitemid 40686302)
62. Isidori A. M., Caprio M., Strollo F., Moretti C., Frajese G., Isidori A., Fabbri A., Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism 1999 84 10 3673 3680 2-s2.0-0033304558 (Pubitemid 30645224)
63. Goncharov N. P., Katsya G. V., Chagina N. A., Gooren L. J., Testosterone and obesity in men under the age of 40 years. Andrologia 2009 41 2 76 83 2-s2.0-61449163879 10.1111/j.1439-0272.2008.00863.x
64. Mah P. M., Wittert G. A., Obesity and testicular function. Molecular and Cellular Endocrinology 2010 316 2 180 186 2-s2.0-67649883478 10.1016/j.mce.2009.06.007
65. Zitzmann M., Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Reviews Endocrinology 2009 5 12 673 681 2-s2.0-70849117428 10.1038/nrendo.2009.212
66. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T.-P., Salonen R., Rauramaa R., Salonen J. T., Sex hormones, inflammation and the metabolic syndrome: a population-based study. European Journal of Endocrinology 2003 149 6 601 608 2-s2.0-0346728590 10.1530/eje.0.1490601 (Pubitemid 38054707)
67. Smith M. R., Lee H., Nathan D. M., Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 4 1305 1308 2-s2.0-33646029746 10.1210/jc.2005-2507
68. Braga-Basaria M., Dobs A. S., Muller D. C., Carducci M. A., John M., Egan J., Basaria S., Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology 2006 24 24 3979 3983 2-s2.0-33748474608 10.1200/JCO.2006.05.9741 (Pubitemid 46630747)
69. Yialamas M. A., Dwyer A. A., Hanley E., Lee H., Pitteloud N., Hayes F. J., Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 2007 92 11 4254 4259 2-s2.0-35948930594 10.1210/jc.2007-0454 (Pubitemid 350074740)
70. Haidar A., Yassin A., Saad F., Shabsigh R., Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007 10 4 189 196 2-s2.0-36348951600 10.1080/13685530701653538 (Pubitemid 350146723)
71. Wu F. C. W., Tajar A., Pye S. R., Silman A. J., Finn J. D., O'Neill T. W., Bartfai G., Casanueva F., Forti G., Giwercman A., Huhtaniemi I. T., Kula K., Punab M., Boonen S., Vanderschueren D., Petrone L., Cilotti A., Borghs H., Slowikowska-Hilczer J., Walczak-Jedrzejowska R., Wu F., Silman A., O'Neill T., Finn J., Steer P., Lee D., Pye S., Ocampo M., Lage M., Bartfai G., Földesi I., Fejes I., Korrovitz P., Jiang M., Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2737 2745 2-s2.0-47549107694 10.1210/jc.2007-1972 (Pubitemid 352008544)
72. Travison T. G., Araujo A. B., Kupelian V., O'Donnell A. B., McKinlay J. B., The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. Journal of Clinical Endocrinology and Metabolism 2007 92 2 549 555 2-s2.0-33846961810 10.1210/jc.2006-1859
73. Cicero A. F. G., afgcicero@cardionet.it Derosa G., Bove M., Di Gregori V., Gaddi A. V., Borghi C., Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. European Journal of Cardiovascular Prevention and Rehabilitation 2009 16 6 698 704 2-s2.0-48549105169 10.1097/HJR.0b013e32833158e4
74. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., D'Armiento M., D'Andrea F., Giugliano D., Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004 292 12 1440 1446 2-s2.0-4544288392 10.1001/jama.292.12.1440 (Pubitemid 39258336)
75. Heufelder A. E., Saad F., Bunck M. C., Gooren L., louisjgooren@gmail.com Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of Andrology 2009 30 6 726 733 2-s2.0-33751533215 10.2164/jandrol.108.007005
76. Marin P., Lönn L., Andersson B., Odén B., Olbe L., Bengtsson B.-Å., Björntorp P., Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. Journal of Clinical Endocrinology and Metabolism 1996 81 3 1018 1022 2-s2.0-0029975938 10.1210/jc.81.3.1018 (Pubitemid 26083964)
77. Singh R., Artaza J. N., Taylor W. E., Braga M., Yuan X., Gonzalez-Cadavid N. F., Bhasin S., Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with β -catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006 147 1 141 154 2-s2.0-29344440814 10.1210/en.2004-1649 (Pubitemid 43004269)
78. Svartberg J., Agledahl I., Figenschau Y., Sildnes T., Waterloo K., Jorde R., Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. International Journal of Impotence Research 2008 20 4 378 387 2-s2.0-48349144149 10.1038/ijir.2008.19
79. Isidori A. M., Giannetta E., Greco E. A., Gianfrilli D., Bonifacio V., Isidori A., Lenzi A., Fabbri A., Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clinical Endocrinology 2005 63 3 280 293 2-s2.0-24144489427 10.1111/j.1365-2265. 2005.02339.x (Pubitemid 41233445)
80. Jones T. H., Saad F., The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009 207 2 318 327 2-s2.0-70549086629 10.1016/j.atherosclerosis.2009.04.016
81. Allan C. A., Strauss B. J. G., Burger H. G., Forbes E. A., McLachlan R. I., Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. Journal of Clinical Endocrinology and Metabolism 2008 93 1 139 146 2-s2.0-38149032364 10.1210/jc.2007-1291
82. Munzer T., Harman S. M., Hees P., Shapiro E., Christmas C., Bellantoni M. F., Stevens T. E., O'Connor K. G., Pabst K. M., St. Clair C., Sorkin J. D., Blackman M. R., Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. Journal of Clinical Endocrinology and Metabolism 2001 86 8 3604 3610 2-s2.0-17944362705 10.1210/jc.86.8.3604 (Pubitemid 32755950)
83. Schroeder E. T., Zheng L., Ong M. D., Martinez C., Flores C., Stewart Y., Azen C., Sattler F. R., Effects of androgen therapy on adipose tissue and metabolism in older men. Journal of Clinical Endocrinology and Metabolism 2004 89 10 4863 4872 2-s2.0-6344284391 10.1210/jc.2004-0784 (Pubitemid 39391420)
84. Haider A., Gooren L. J.G., Padungtod P., Saad F., Farid. Saad@bayerhealthcare.com Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Experimental and Clinical Endocrinology and Diabetes 2010 118 3 167 171 2-s2.0-48349144149 10.1055/s-0029-1202774
85. Pitteloud N., Mootha V. K., Dwyer A. A., Hardin M., Lee H., Eriksson K.-F., Tripathy D., Yialamas M., Groop L., Elahi D., Hayes F. J., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005 28 7 1636 1642 2-s2.0-24944450769 10.2337/diacare.28.7. 1636 (Pubitemid 41340902)
86. Boyanov M. A., Boneva Z., Christov V. G., Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003 6 1 1 7 2-s2.0-0038823605 (Pubitemid 36606394)
87. Moon D. G., dgmoon@korea.ac.kr Park M. G., Lee S. W., Park K., Park J. K., Kim S. W., Park N. C., Ahn T. Y., Paick J. S., Seo J. T., Yang D. Y., Lee J. Y., Kim J. J., The efficacy and safety of testosterone undecanoate (Nebido ®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. Journal of Sexual Medicine 2010 7 6 2253 2260 2-s2.0-0021237827 10.1111/j.1743-6109.2010.01765.x
88. Corrales J. J., Almeida M., Burgo R., Mories M. T., Miralles J. M., Orfao A., Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men and partial androgen deficiency. Journal of Endocrinology 2006 189 3 595 604 2-s2.0-33745259011 10.1677/joe.1.06779 (Pubitemid 43922123)
89. Lee C.-H., Kuo S.-W., Hung Y.-J., Hsieh C.-H., He C.-T., Yang T.-C., Lian W.-C., Chyi-Fan S., Pei D., The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Research 2005 31 2 139 148 2-s2.0-28744448704 10.1080/07435800500320653 (Pubitemid 41759228)
90. Laughlin G. A., Barrett-Connor E., Bergstrom J., Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology and Metabolism 2008 93 1 68 75 2-s2.0-38148998650 10.1210/jc.2007-1792
91. Shores M. M., Moceri V. M., Gruenewald D. A., Brodkin K. I., Matsumoto A. M., Kivlahan D. R., Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. Journal of the American Geriatrics Society 2004 52 12 2077 2081 2-s2.0-16644396636 10.1111/j.1532-5415.2004.52562.x (Pubitemid 41725027)
92. Shores M. M., Matsumoto A. M., Sloan K. L., Kivlahan D. R., Low serum testosterone and mortality in male veterans. Archives of Internal Medicine 2006 166 15 1660 1665 2-s2.0-33747158767 10.1001/archinte.166.15.1660 (Pubitemid 44232378)
93. Khaw K.-T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N., Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: european prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007 116 23 2694 2701 2-s2.0-37349118353 10.1161/CIRCULATIONAHA.107.719005 (Pubitemid 350291241)
94. Maggio M., Lauretani F., Ceda G. P., Bandinelli S., Ling S. M., Metter E. J., Artoni A., Carassale L., Cazzato A., Ceresini G., Guralnik J. M., Basaria S., Valenti G., Ferrucci L., Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the chianti area (InCHIANTI) study. Archives of Internal Medicine 2007 167 20 2249 2254 2-s2.0-36148989115 10.1001/archinte.167.20.2249 (Pubitemid 350106746)
95. Muller M., den Tonkelaar I., Thijssen J. H. H., Grobbee D. E., van der Schouw Y. T., Endogenous sex hormones in men aged 40-80 years. European Journal of Endocrinology 2003 149 6 583 589 2-s2.0-0346728591 10.1530/eje.0.1490583 (Pubitemid 38054704)
96. Mulligan T., Frick M. F., Zuraw Q. C., Stemhagen A., McWhirter C., Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Practice 2006 60 7 762 769 2-s2.0-33745108447 10.1111/j.1742-1241.2006.00992.x (Pubitemid 43881152)
97. Vermeulen A., Androgen replacement therapy in the aging male-a critical evaluation. Journal of Clinical Endocrinology and Metabolism 2001 86 6 2380 2390 2-s2.0-0034967072 10.1210/jc.86.6.2380 (Pubitemid 32545680)
98. Nieschlag E., Swerdloff R., Behre H. M., Gooren L. J., Kaufman J. M., Legros J.-J., Lunenfeld B., Morley J. E., Schulman C., Wang C., Weidner W., Wu F. C. W., Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. European Urology 2005 48 1 1 4 2-s2.0-20644433950 10.1016/j.eururo.2005.04.027 (Pubitemid 40835584)
99. Vermeulen A., Verdonck L., Kaufman J. M., A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 10 3666 3672 2-s2.0-0033305020 (Pubitemid 30645223)
100. Sodergard R., Backstrom T., Shanbhag V., Carstensen H., Calculation of free and bound fractions of testosterone and estradiol-17 β to human plasma proteins at body temperature. Journal of Steroid Biochemistry 1982 16 6 801 810 2-s2.0-0020417830 10.1016/0022-4731(82)90038-3 (Pubitemid 13228095)
101. Schultheiss D., Machtens S., Jonas U., Testosterone therapy in the ageing male: what about the prostate? Andrologia 2004 36 6 355 365 2-s2.0-9144254670 10.1111/j.1439-0272.2004.00630.x (Pubitemid 39540773)
102. Morales A., Testosterone treatment for the aging man: the controversy. Current Urology Reports 2004 5 6 472 477 2-s2.0-16644373827
103. Calof O. M., Singh A. B., Lee M. L., Kenny A. M., Urban R. J., Tenover J. L., Bhasin S., Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology 2005 60 11 1451 1457 2-s2.0-29144469309 (Pubitemid 41798454)
104. Ebling D. W., Ruffer J., Whittington R., Vanarsdalen K., Broderick G. A., Malkowicz S. B., Wein A. J., Development of prostate cancer after pituitary dysfunction: a report of 8 patients. Urology 1997 49 4 564 568 2-s2.0-0030889373 10.1016/S0090-4295(96)00541-9 (Pubitemid 27161415)
105. Loughlin K. R., Richie J. P., Prostate cancer after exogenous testosterone treatment for impotence. The Journal of Urology 1997 157 5 1845 2-s2.0-0030899378 10.1016/S0022-5347(01)64881-X (Pubitemid 27171790)
106. Curran M. J., Bihrle W. III, Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999 53 2 423 424 2-s2.0-0032943937 10.1016/S0090-4295(98) 00348-3 (Pubitemid 29063343)
107. Rhoden E. L., Morgentaler A., Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 2004 350 5 482 492 2-s2.0-1642458222 10.1056/NEJMra022251 (Pubitemid 38133769)
108. Sengupta S., Duncan H. J., Macgregor R. J., Russell J. M., The development of prostate cancer despite late onset androgen deficiency. International Journal of Urology 2005 12 9 847 848 2-s2.0-28444435134 10.1111/j.1442-2042.2005.01172.x (Pubitemid 41726984)
109. Carter H. B., Pearson J. D., Metter E. J., Chan D. W., Andres R., Fozard J. L., Rosner W., Walsh P. C., Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995 27 1 25 31 2-s2.0-0029033044 10.1002/pros.2990270106
110. Hsing A. W., Hormones and prostate cancer: what's next? Epidemiologic Reviews 2001 23 1 42 58 2-s2.0-0030596716 (Pubitemid 32906613)
111. Tenover J. S., Effects of testosterone supplementation in the aging male. Journal of Clinical Endocrinology and Metabolism 1992 75 4 1092 1098 2-s2.0-0026742650 10.1210/jc.75.4.1092
112. Marks L. S., Mazer N. A., Mostaghel E., Hess D. L., Dorey F. J., Epstein J. I., Veltri R. W., Makarov D. V., Partin A. W., Bostwick D. G., Macairan M. L., Nelson P. S., Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006 296 19 2351 2361 2-s2.0-33750978404 10.1001/jama.296.19.2351 (Pubitemid 44749363)
113. Morgentaler A., Testosterone replacement therapy and prostate cancer. Urologic Clinics of North America 2007 34 4 555 563 2-s2.0-35648968683 10.1016/j.ucl.2007.08.002 (Pubitemid 350029943)
114. Yassin A., Saad F., Testosterone treatment in hypogonadal patients does not cause higher incidence of prostate cancer. The Journal of Urology 2008 179 4 301
115. Yassin A. A., Saad F., Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. Journal of Sexual Medicine 2007 4 2 497 501 2-s2.0-33947169475 10.1111/j.1743-6109.2007.00442.x (Pubitemid 46394724)
116. Coward R. M., Simhan J., Carson C. C. III, Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU International 2009 103 9 1179 1183 2-s2.0-64249137805 10.1111/j.1464-410X.2008.08240.x
117. Leibowitz R. L., Dorff T. B., dorff@usc.edu Tucker S., Symanowski J., Vogelzang N. J., Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU International 2010 105 10 1397 1401 2-s2.0-37349107226 10.1111/j.1464-410X.2009.08980.x
118. Rhoden E. L., Averbeck M. A., Testosterone therapy and prostate carcinoma. Current Urology Reports 2009 10 6 453 459 2-s2.0-70449495611 10.1007/s11934-009-0072-1
119. Isbarn H., Pinthus J. H., Marks L. S., Montorsi F., Morales A., Morgentaler A., Schulman C., Testosterone and prostate cancer: revisiting old paradigms. European Urology 2009 56 1 48 56 2-s2.0-67349282280 10.1016/j.eururo.2009.03.088
120. Morgentaler A., Rapidly shifting concepts regarding androgens and prostate cancer. The Scientific World Journal 2009 9 685 690 2-s2.0-70350749679 10.1100/tsw.2009.80
121. Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J., Swerdloff R. S., Montori V. M., Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 6 1995 2010 2-s2.0-33744948333 10.1210/jc.2005-2847 (Pubitemid 43854972)
122. Wang C., Nieschlag E., Swerdloff R., Behre H. M., Hellstrom W. J., Gooren L. J., Kaufman J. M., Legros J.-J., Lunenfeld B., Morales A., Morley J. E., Schulman C., Thompson I. M., Weidner W., Wu F. C. W., Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. European Journal of Endocrinology 2008 159 5 507 514 2-s2.0-56749163628 10.1530/EJE-08-0601
123. Kaufman J. M., Graydon R. J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. The Journal of Urology 2004 172 3 920 922 2-s2.0-4143066958 10.1097/01.ju.0000136269.10161.32 (Pubitemid 39096423)
124. Agarwal P. K., Oefelein M. G., michael.oefelein@uhhs.com Testosterone replacement therapy after primary treatment for prostate cancer. The Journal of Urology 2005 173 2 533 536 2-s2.0-0036844762 10.1097/01.ju.0000143942.55896.64
125. Sarosdy M. F., urodoc@satx.rr.com Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007 109 3 536 541 2-s2.0-0032955357 10.1002/cncr.22438 (Pubitemid 46190961)
126. Wang C., Nieschlag E., Swerdloff R., Behre H. M., Hellstrom W. J., Gooren L. J., Kaufman J. M., Legros J.-J., Lunenfeld B., Morales A., Morley J. E., Schulman C., Thompson I. M., Weidner W., Wu F. C. W., Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. European Urology 2009 55 1 121 130 2-s2.0-56249088599 10.1016/j.eururo.2008.08.033